Congenital cytomegalovirus infection (late-onset hearing impairment)
Conditions
Interventions
Valganciclovir 16 mg/kg is to be continuously administered twice daily for 6 months.
Equivalent dose (mL) of valganciclovir (16 mg/kg) which be calculated based on body weight is to be continuously a
Sponsors
Fujioka Kazumichi
Nozu Kandai
Morioka Ichiro
Oka Akira
Morimoto Noriko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Confirmation of positive CMV-DNA amplification in urine by an in vitro diagnostic test within 21 days of age or in dried umbilical cord tissue or dried filter paper blood 2. Patients who were asymptomatic at birth but developed late-onset hearing impairment after 21 days of age, or patients who were symptomatic at birth but did not have any hearing impairment and subsequently developed late-onset hearing impairment 3. Patients with a degree of impairment of at least 30 dB in at least one ear at the time of screening 4. Preschool patients under 7 years old at the time of obtaining informed consent 5. Signed informed consent from parents or legal guardians
Exclusion criteria
Exclusion criteria: 1. Patients with bacterial infection requiring antibiotics at the time of study enrollment 2. Renal insufficiency (serum creatinine level > 1.5 mg/dL) at the time of study enrollment 3. Encephalopathy and hydrocephalus owing to other causes 4. Patients with inner ear malformations such as enlarged vestibular aqueducts, middle ear malformations, and middle ear diseases such as cholesteatoma 5. Mumps deafness 6. Hereditary or progressive central deafness 7. Patients who have received treatment with an antiviral drug (such as ganciclovir or valganciclovir) for CMV in the past. However, this is acceptable for temporary treatment of active or acute lesions. 8. Neutrophil count < 500/mm3 or platelet count < 25,000/mm3 9. Infants born to women with human immunodeficiency virus (HIV) or infants with HIV 10. Patients receiving breast milk from mothers who are taking antiviral or immunosuppressive drugs 11. Patients who have received other investigational drugs before registration, or who plan to participate in other clinical trials during the period of participation in the clinical trial 12. Patients deemed inappropriate by a study investigator or sub-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hearing improvement in ABR (total ear hearing assessments) or ASSR after 6 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Hearing improvement in ABR or ASSR (total ear hearing assessments) after 6 weeks of treatment 2. Hearing improvement in ABR or ASSR (best response ear hearing assessments) after 6 weeks and 6 months of treatment 3. Changes in hearing impairment levels in ABR (total ear hearing assessments) after 6 weeks and 6 months of treatment 4. Change in hearing impairment levels in ABR (best response ear hearing assessments) after 6 weeks and 6 months of treatment 5. Changes in hearing impairment levels in ASSR for each frequency (500Hz, 1000Hz, 2000Hz, 4000Hz) (both best response ear and total ear hearing assessments) after 6 months of treatment 6. CMV load in whole blood during the study period and its change from baseline 7. CMV load in plasma during the study period and its change from baseline 8. CMV load in urine during the study period and its change from baseline 9. Improvement of thrombocytopenia, liver function disorder, and retinitis Adverse events, Adverse drug reactions | — |
Contacts
Public ContactTomoyuki Kodama
Kobe University Hospital
Outcome results
None listed